For his research on poisonous snakes Dr. Freek Vonk, researcher at Naturalis Biodiversity Center, received a VENI grant of a quarter million from the Dutch Organization for Scientific Research (NWO). Freek Vonk will use this amount to clarify the genomes of two species of poisonous snake species.
> Read more Dutch
MorphoSys and Galapagos advance Joint antibody program in Inflammatory diseases into preclinical developmentPublished : Wednesday, July 23, 2014
MorphoSys AG and Galapagos NV announced that the first program from their strategic alliance has advanced into preclinical development. MOR106 was realized based on a novel Galapagos target and MorphoSys' next-generation antibody library Ylanthia and will now be jointly developed in inflammatory diseases.
Pharming and Salix announce FDA approval of Ruconest® for the treatment of acute Angioedema Attacks in patients with Hereditary Angioedema (HAE)Published : Thursday, July 17, 2014
Pharming Group NV and Salix Pharmaceuticals, Ltd. announced that the Food and Drug Administration has approved RUCONEST® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE). Because of the limited number of patients with laryngeal attacks, effectiveness was not established in HAE patients with laryngeal attacks.
One of the riddles of mammal evolution explained: the strong conservation of the number of trunk vertebrae. Researchers of the Naturalis Biodiversity Center and the University of Utah show that this conservation is probably due to the essential role of speed and agility in survival of fast running mammals.
The first two courses of the Leiden Futurelab, a new international post-graduate learning center for biomedical professionals with an entrepreneurial spirit, took place in June and early July. Both courses were very successful: 'Clinical development & clinical trial application' (CD&CTA) and 'Intellectual Property in high tech start-ups' (IP). The courses offered a stimulating environment for the participants.
Leiden Bio Science Park and InnovationQuarter together with other regional organizations joined the Dutch Ministry and Holland Bio at the Holland Pavilion at the BIO International Convention 2014 in San Diego. In this joined effort The Netherlands was well represented and profiled as a biotech hub for international companies at the world’s largest and most prestigious biotechnology event.
Registration for the 5th edition of Science for Business-BioWin Day began on May, 12th. The event accounts already, six months prior, 31 exhibitors and 37 sponsors (including GSK, Baxter, IBA, Janssen Pharma, Novartis, Merck Belgium, Merck Millipore, Eurogentec Kaneka, etc.). Check out the program and join us on November 26th, 2014, at Aula Magna (in Louvain-la-Neuve, Belgium)!
On an excavation site in the Oegstgeest area of Leiden Bio Science Park, Leiden University archaeologists discovered a very rare silver bowl from the first half of the seventh century. The bowl is decorated with gold-plated representations of animals and plants and inlaid with semi-precious stones. The discovery suggests the existence of an elite with a wide international network in Oegstgeest.
Prosensa Holding N.V. the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and the addition of Dr. Annalisa Jenkins to its Supervisory Board. With more than two decades of experience at Genzyme and GSK and his recent leadership of Dutch to-BBB as CEO, Mr. van Weperen brings significant business operational and commercial expertise to Prosensa in advance of an anticipated launch of the company's first product for the treatment of Duchenne muscular dystrophy (DMD).
to-BBB, a biotechnology company developing novel treatments for devastating brain diseases, announced the successful finalization of a round C financing of €10 million with new and existing investors. The company also announced the appointment of Dr. Pericles (Perry) Calias as Senior Vice President Translational Medicine and the appointment of Leonard Kruimer as interim CEO to replace Willem van Weperen, who accepted a career opportunity outside the company.
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe